intrathecal administration of nusinersen in adult spinal muscular atrophy (SMA) patients with scoliosis and spondylodesis requires image guidance, which is preferably achieved with multi-detector computed tomography (MDct). As long-term treatment is necessary and patients are young, radiation doses should be reduced to a minimum whilst a sufficient image quality for precise interventional performance should be kept. We compared 44 MDCT standard-dose scans (133.0-200.0 mA) with a hybrid iterative reconstruction (iDose4) to 20 low-dose scans (20.0-67.0 mA) with iterative model reconstruction (IMR), which were performed for procedure planning of intrathecal nusinersen administration in 13 adult patients with SMA and complex spinal conditions. Qualitative image evaluation, including confidence for intervention planning, was performed by two neuroradiologists for standard-and low-dose scans. All 64 MDCT-guided intrathecal administrations of nusinersen were successful. The dose length product (DLP) was significantly lower when using low-dose scanning with IMR (median DLP of standard-dose scans: 92.0 mGy•cm vs. low-dose scans: 34.5 mGy•cm; p < 0.0001). Image quality was significantly reduced for low-dose compared to standard-dose scanning. However, bone/soft tissue contrast and confidence for intervention planning were not significantly impaired in low-dose MDCT according to both readers, showing good inter-reader agreement. thus, we hereby demonstrate a low-dose MDct protocol combined with advanced image reconstruction for scanning during procedure planning as a viable option for image guidance in intrathecal nusinersen treatment of adult SMA patients with complex spinal conditions. Spinal muscular atrophy (SMA) is an autosomal-recessive neurodegenerative disease caused by mutations in the survival motor neuron 1 (SMN1) gene 1. The lack of SMN protein results in progressive degeneration of motor neurons causing muscle weakness and atrophy with varying severity. In June 2017, the European Medicines Agency approved nusinersen as the first drug to treat SMA. Nusinersen, an antisense oligonucleotide (ASO), does not efficiently cross the blood-brain barrier and thus has to be administered directly into the cerebrospinal fluid (CSF), which is commonly achieved by a lumbar puncture (LP). Intrathecal drug administration presents challenges in adult SMA patients due to severe neuromuscular scoliosis and frequent preceding spinal fusion surgeries. Recent studies showed intrathecal treatment with nusinersen to be feasible and safe when using image guidance in patients with scoliosis 2,3. Generally, guidance by computed tomography (CT) was evaluated to be superior to fluoroscopy-assistance in patients with a complex spinal architecture 2,3. However, CT-guided interventions are accompanied by radiation exposure and, therefore, radiation risks need to be taken into account, such as an increased risk of cancer induction 4,5. Particularly in patients with SMA efforts must be made to keep radiation exposure as low as possible since pat...